

## ColoSTAT<sup>®</sup> Demonstrates Early Clinical Adoption in Commercial Rollout, Expanding Across Underserved Patient Segments

### Highlights

- ✓ Early signs of clinical adoption emerging through commercial deployment with 4Cyte Pathology
- ✓ ColoSTAT<sup>®</sup> expanding into underserved patient groups, including elderly, mobility-limited and home-based patients
- ✓ Demonstrates growing real-world demand for non-invasive, blood-based CRC triage
- ✓ Validates scalable collection pathways, including home and community-based testing
- ✓ Strengthens positioning as a frontline triage tool for symptomatic colorectal cancer patients
- ✓ Supports pathway toward broader clinical adoption and commercial scale

**Melbourne, Australia, 6<sup>th</sup> May 2026:** Rhythm Biosciences Ltd (ASX: RHY) is pleased to announce that its ColoSTAT<sup>®</sup> blood-based colorectal cancer (CRC) triage test is demonstrating early signs of clinical adoption in real-world settings, following its commercial deployment with 4Cyte Pathology.

The Company reports that ColoSTAT<sup>®</sup> is being utilised across a broader range of patient scenarios, including underserved populations where traditional diagnostic pathways present significant barriers. These early use cases provide initial indicators of repeatable clinical demand and highlight the test's potential to scale within existing healthcare infrastructure.

### From Clinical Validation to Real-World Utilisation

ColoSTAT<sup>®</sup> is designed to support clinicians in triaging symptomatic patients for colorectal cancer, enabling earlier and more accessible diagnostic decision-making.

Rhythm previously described four use cases in the Company's announcement dated 16<sup>th</sup> February 2026 and has now supported examples of two of the more complex patient segments, reinforcing the test's growing clinical relevance and practical applicability.

Importantly, these outcomes are being observed within a commercial pathology environment, representing an early-stage step toward broader real-world adoption and commercialisation.

### Case Study Insights

#### 1. Elderly, Remote Patient - Far North NSW

An elderly patient in his eighties, located in regional New South Wales, presented with symptoms consistent with CRC. Due to age and distance from pathology infrastructure, the patient sought a non-invasive alternative to immediate colonoscopy.

A home blood collection was successfully conducted, enabling access to diagnostic triage without the need for travel or invasive procedures.

#### Directors

**This demonstrates ColoSTAT®'s ability to provide accessible diagnostic triage for elderly and geographically isolated patients, where traditional pathways may be delayed or difficult to access.**

## **2. Mobility-Limited Patient - Sunshine Coast, QLD**

A patient with significant mobility limitations and other health complications, underwent ColoSTAT® testing via a local collection centre, avoiding the need for complex procedural preparation or hospital-based diagnostics.

**This highlights ColoSTAT®'s suitability for patients with complex health profiles, where conventional diagnostic pathways may present additional clinical or logistical challenges.**

## **Scalable and Accessible Testing Model**

These cases highlight ColoSTAT®'s ability to integrate into existing pathology infrastructure, including:

- Home-based blood collection
- Community pathology centres

By removing key barriers associated with stool-based testing and invasive procedures, ColoSTAT® has the potential to:

- Improve patient access and adoption
- Enable earlier triage decisions
- Support more efficient use of colonoscopy resources

## **CEO Commentary**

Rhythm Biosciences CEO & Managing Director, Dr David Atkins, said:

“We are beginning to see early signs of how ColoSTAT® is being adopted in real-world clinical settings, particularly in patient groups where traditional diagnostic pathways present challenges.

These early cases are consistent with emerging demand for a simple, blood-based triage tool that can be used at the point of initial assessment. A key advantage of ColoSTAT® is its ability to reduce reliance on invasive procedures and stool-based testing, supporting more accessible diagnostic pathways for patients.

As our commercial programme with 4Cyte Pathology continues to expand, we are focused on building further real-world evidence to support broader clinical adoption.”

## **Investor Webinar Update**

The Company invites shareholders to attend its upcoming quarterly investor webinar, where Dr David Atkins and members of the team will provide an update on recent progress, including developments from the Company's commercial programme, as well as broader market insights.

Shareholders are encouraged to register in advance and submit questions to be addressed during the session. Time permitting, additional questions may be taken live during the webinar.

**Date:** Wednesday, 13 May 2026

**Time:** 10:00am AEST

**Registration:** [https://us06web.zoom.us/webinar/register/WN\\_8WpRdSPCS-2vURX6kGbpmQ](https://us06web.zoom.us/webinar/register/WN_8WpRdSPCS-2vURX6kGbpmQ)

Alternatively, investors can submit questions via email to [investors@rhythmbio.com](mailto:investors@rhythmbio.com)

- ENDS -

**This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.**

**For further information contact us via [investors@rhythmbio.com](mailto:investors@rhythmbio.com)**

**About Rhythm Biosciences**

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer, and saving lives. Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions. The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit [rhythmbio.com](http://rhythmbio.com) and follow the company on LinkedIn and X.

**About ColoSTAT®**

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer can be curable. The ColoSTAT® Test is Rhythm Bioscience's simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. It is intended for individuals with symptoms associated with Colorectal Cancer (CRC). The ColoSTAT® Test is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

**About geneType™**

geneType™ is a sophisticated genetic risk assessment testing platform that combines clinical, family history and genetic data to provide comprehensive risk assessments for various diseases. The platform leverages polygenic risk scores and clinical risk factors to generate personalized health insights, helping individuals and healthcare providers make more informed medical decisions. The technology allows for risk assessment across multiple conditions including breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer, and melanoma. The tests are delivered through healthcare providers and genetic counsellors, ensuring appropriate clinical oversight and support for patients receiving their results. The platform's multi-disease assessment capabilities and clinical utility position it well to capture growing demand in the preventative healthcare and precision medicine markets. For more information, please visit [www.genetype.com](http://www.genetype.com).